NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -35.96% | -29.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.63% | -29.99% | |||
| Operating Income | 38.18% | 29.99% | |||
| Income Before Tax | 32.13% | 41.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.13% | 41.02% | |||
| Earnings from Discontinued Operations | -4.76% | -99.62% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.73% | -125.06% | |||
| EBIT | 38.18% | 29.99% | |||
| EBITDA | 38.25% | 29.97% | |||
| EPS Basic | 33.41% | -122.87% | |||
| Normalized Basic EPS | 37.20% | 34.61% | |||
| EPS Diluted | 32.93% | -123.03% | |||
| Normalized Diluted EPS | 37.20% | 33.31% | |||
| Average Basic Shares Outstanding | 1.00% | 9.61% | |||
| Average Diluted Shares Outstanding | 1.00% | 7.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||